Arcutis Biotherapeutics Inc
ARQT
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.32B
Close$
$-28.99
199.6% downside
Current Fair Value
199.6% downsideOvervalued by 199.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.32 Billion |
|---|---|
| Enterprise Value | $3.40 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.13 |
| Beta | 1.58 |
| Outstanding Shares | 130,522,000 |
Return
| Return on Equity | 12.93% |
|---|---|
| Return on Assets | 5.84% |
| Return on Invested Capital | 11.86% |
Valuation & Multiples
| P/E Ratio | 120.38 |
|---|---|
| PEG | -61.9 |
| Price to Sales | 9.7 |
| Price to Book Ratio | 29.1 |
| Enterprise Value to Revenue | 7.34 |
| Enterprise Value to EBIT | 87.47 |
| Enterprise Value to Net Income | 119 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.52 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$118.85 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$0.18
Average shareholder expectationRevenue Estimate
$141.94 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 8.42% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 101.50% |
|---|---|
| Total Invested | $355,380▼ 99.99% |
| Investors Holding | 7▼ 275.00% |
ESG Score
No data